{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:51:53Z","timestamp":1781643113303,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Science Foundation of Kangda College of Nanjing Medical University","award":["No. KD2025KYJJ209"],"award-info":[{"award-number":["No. KD2025KYJJ209"]}]},{"name":"Changzhou Sci&Tech Program","award":["No. CJ20220226"],"award-info":[{"award-number":["No. CJ20220226"]}]},{"name":"the Science and Technology Project of Changzhou Municipal Health Commission","award":["No. QN202238"],"award-info":[{"award-number":["No. QN202238"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B (HBV) is frequently accompanied by immune dysregulation, and autoantibodies are intermittently detected in clinical practice. However, the clinical significance of autoantibody positivity across different HBV-related disease stages and its relationship with non-invasive fibrosis indices remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 151 patients with HBV-related liver disease, including chronic hepatitis B (CHB), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). Antinuclear antibodies (ANA) and extended autoantibody profiles were evaluated together with the aspartate aminotransferase\u2013to\u2013platelet ratio index (APRI) and fibrosis-4 index (FIB-4). Clinical and laboratory parameters were compared across disease groups, and receiver operating characteristic (ROC) curves were constructed to assess the diagnostic performance of APRI and FIB-4 for identifying advanced liver disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ANA positivity increased progressively from CHB to LC and HCC, whereas extended autoimmune liver\u2013specific autoantibodies remained rare across all stages. APRI and FIB-4 showed stepwise elevation with advancing disease severity, with FIB-4 demonstrating better diagnostic performance for advanced liver disease. ANA positivity showed no significant association with fibrosis indices, suggesting that these features may reflect distinct aspects of disease-related immune dysregulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ANA positivity in chronic HBV infection appears to primarily reflect nonspecific immune activation rather than true autoimmune liver disease. FIB-4 provides practical and readily available information for identifying advanced liver disease, particularly in settings where liver biopsy or elastography is unavailable. Consideration of autoantibody patterns in conjunction with fibrosis indices may aid laboratory interpretation and support more informed clinical assessment in HBV-related liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04718-4","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:16:14Z","timestamp":1773216974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoantibody profiles and fibrosis indices across HBV-related disease stages: a retrospective laboratory-based study in a tertiary hospital in China"],"prefix":"10.1186","volume":"26","author":[{"given":"Hui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"4718_CR1","volume-title":"Global hepatitis report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017."},{"issue":"11","key":"4718_CR2","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","volume":"350","author":"D Ganem","year":"2004","unstructured":"Ganem D, Prince AM. Hepatitis B virus infection\u2014natural history and clinical consequences. N Engl J Med. 2004;350(11):1118\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"4718_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.gastro.2018.08.061","volume":"156","author":"B Rehermann","year":"2019","unstructured":"Rehermann B, Thimme R. Insights from antiviral therapy into immune responses to hepatitis B virus infection. Gastroenterology. 2019;156(2):369\u201383.","journal-title":"Gastroenterology"},{"issue":"1","key":"4718_CR4","first-page":"170","volume":"132","author":"P Muratori","year":"2003","unstructured":"Muratori P, Muratori L, Guidi M, et al. Smooth muscle antibodies and antinuclear antibodies in chronic hepatitis B and C. Clin Exp Immunol. 2003;132(1):170\u20135.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"4718_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.14218\/JCTH.2014.00032","volume":"3","author":"R Liberal","year":"2015","unstructured":"Liberal R, Vergani D, Mieli-Vergani G. Update on autoimmune hepatitis. J Clin Transl Hepatol. 2015;3(1):42\u201352.","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"4718_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169\u201376.","journal-title":"Hepatology"},{"issue":"2","key":"4718_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"issue":"6","key":"4718_CR8","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"2","key":"4718_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"2","key":"4718_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406\u201360.","journal-title":"J Hepatol"},{"issue":"1","key":"4718_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"8","key":"4718_CR12","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S, et al. Familiarity breeds strategy: in silico untangling of the molecular complexity of autoimmune liver disease\u2013to\u2013hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10(8):1917.","journal-title":"Cells"},{"issue":"2","key":"4718_CR13","first-page":"123","volume":"8","author":"L Muratori","year":"2009","unstructured":"Muratori L, Granito A, Pappas G, Muratori P, Lenzi M, Bianchi FB. Autoimmune liver disease: overlap syndromes and diagnostic issues. Autoimmun Rev. 2009;8(2):123\u20137.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"4718_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5009\/gnl15352","volume":"10","author":"AJ Czaja","year":"2016","unstructured":"Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver. 2016;10(2):177\u2013203.","journal-title":"Gut Liver"},{"issue":"3","key":"4718_CR15","first-page":"473","volume":"30","author":"L Zhang","year":"2015","unstructured":"Zhang L, Wang J, Wang J, et al. Prevalence and clinical significance of autoantibodies in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(3):473\u20138.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"4718_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","volume":"30","author":"BK Kim","year":"2010","unstructured":"Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus\u2013infected patients. Liver Int. 2010;30(4):546\u201353.","journal-title":"Liver Int"},{"issue":"4","key":"4718_CR17","first-page":"772","volume":"61","author":"YE Chon","year":"2014","unstructured":"Chon YE, Jung KS, Kim MJ, et al. Predictors of liver-related events in chronic hepatitis B patients with compensated cirrhosis. J Hepatol. 2014;61(4):772\u20138.","journal-title":"J Hepatol"},{"issue":"6","key":"4718_CR18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.25536","volume":"55","author":"KS Jung","year":"2012","unstructured":"Jung KS, Kim SU, Song K, et al. Validation of FIB-4 index for predicting hepatocellular carcinoma in patients with chronic hepatitis B. Hepatology. 2012;55(6):1809\u201317.","journal-title":"Hepatology"},{"issue":"2","key":"4718_CR19","first-page":"363","volume":"63","author":"B Suh","year":"2015","unstructured":"Suh B, Park S, Shin DW, et al. High liver fibrosis index FIB-4 is associated with hepatocellular carcinoma risk in chronic hepatitis B patients. J Hepatol. 2015;63(2):363\u201370.","journal-title":"J Hepatol"},{"issue":"6","key":"4718_CR20","first-page":"2326","volume":"68","author":"GA Kim","year":"2018","unstructured":"Kim GA, Lim YS, Han S, et al. High FIB-4 score is associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Hepatology. 2018;68(6):2326\u201338.","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"4718_CR21","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","volume":"64","author":"A Bertoletti","year":"2016","unstructured":"Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016;64(1 Suppl):S71\u201383.","journal-title":"J Hepatol"},{"issue":"11","key":"4718_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","volume":"16","author":"MK Maini","year":"2019","unstructured":"Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16(11):662\u201375.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04718-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04718-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04718-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:56:34Z","timestamp":1781639794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04718-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4718"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04718-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Changzhou Third People\u2019s Hospital (Approval No. 02A-A20230015). All procedures were conducted in accordance with the Declaration of Helsinki.Patient consent was waived due to the retrospective design and use of anonymized data, as approved by the institutional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}